Literature DB >> 19944311

Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor γ in endothelial cells.

Dahai Wang1, Tetsuaki Hirase, Takeaki Nitto, Masaaki Soma, Koichi Node.   

Abstract

ω-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have beneficial effects on cardiovascular diseases. Cytochrome P-450 (CYP) 2J2 that is expressed in endothelial cells metabolizes arachidonic acids to biologically active epoxyeicosatrienoic acids (EETs) that possess anti-inflammatory and anti-thrombotic effects. We studied the effects of EPA and DHA on the expression of CYP 2J2 mRNA by reverse transcription-polymerase chain reaction in cultured human umbilical vein endothelial cells and found that EPA, but not DHA, increased the expression of CYP 2J2 mRNA in a dose-dependent and a time-dependent manner. EPA-induced CYP 2J2 expression was significantly inhibited by pretreatment with a peroxisome proliferator-activated receptor (PPAR) γ antagonist, GW9662. EPA, but not DHA, caused a significant increase in cellular levels of 11,12-dihydroxyeicosatrienoic acid that is a stable metabolite of 11,12-EET, which was blocked by pretreatment with GW9662. These data demonstrate that EPA increases CYP 2J2 mRNA expression and 11,12-EET production via PPARγ in endothelial cells and indicate a novel protective role of EPA and PPARγ against vascular inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944311     DOI: 10.1016/j.jjcc.2009.06.004

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  7 in total

1.  Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts.

Authors:  Garrett J Gross; Anna Hsu; Adam W Pfeiffer; Kasem Nithipatikom
Journal:  J Mol Cell Cardiol       Date:  2013-02-16       Impact factor: 5.000

2.  CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.

Authors:  Rui Li; Xizhen Xu; Chen Chen; Yan Wang; Artiom Gruzdev; Darryl C Zeldin; Dao Wen Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-11-11       Impact factor: 4.310

3.  1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.

Authors:  Sampath-Kumar Anandan; Heather Kay Webb; Dawn Chen; Yi-Xin Jim Wang; Basker R Aavula; Sylvaine Cases; Ying Cheng; Zung N Do; Upasana Mehra; Vinh Tran; Jon Vincelette; Joanna Waszczuk; Kathy White; Kenneth R Wong; Le-Ning Zhang; Paul D Jones; Bruce D Hammock; Dinesh V Patel; Randall Whitcomb; D Euan MacIntyre; James Sabry; Richard Gless
Journal:  Bioorg Med Chem Lett       Date:  2010-12-13       Impact factor: 2.823

Review 4.  Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer.

Authors:  Guodong Zhang; Sean Kodani; Bruce D Hammock
Journal:  Prog Lipid Res       Date:  2013-12-15       Impact factor: 16.195

5.  Novel Roles of Epoxyeicosanoids in Regulating Cardiac Mitochondria.

Authors:  Haitham E El-Sikhry; Nasser Alsaleh; Rambabu Dakarapu; John R Falck; John M Seubert
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

Review 6.  Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids.

Authors:  Fraser D Russell; Corinna S Bürgin-Maunder
Journal:  Mar Drugs       Date:  2012-11-13       Impact factor: 5.118

7.  4-Hydroxy hexenal derived from docosahexaenoic acid protects endothelial cells via Nrf2 activation.

Authors:  Atsushi Ishikado; Katsutaro Morino; Yoshihiko Nishio; Fumiyuki Nakagawa; Atsushi Mukose; Yoko Sono; Nagisa Yoshioka; Keiko Kondo; Osamu Sekine; Takeshi Yoshizaki; Satoshi Ugi; Takashi Uzu; Hiromichi Kawai; Taketoshi Makino; Tomio Okamura; Masayuki Yamamoto; Atsunori Kashiwagi; Hiroshi Maegawa
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.